leveraging pcsk9-targeting therapies in hyperlipidemia management to reduce cardiovascular risks
Published 1 year ago • 382 plays • Length 33:45Download video MP4
Download video MP3
Similar videos
-
54:32
pcsk9-targeting strategies to achieve lipid goals & reduce cv risks in hyperlipidemia
-
53:13
diagnosing and treating hyperlipidemia: recent evidence and the role of pcsk9-targeted therapies
-
1:37:52
novel therapeutic strategies targeting pcsk9 for reducing ldl-c in hyperlipidemia and ascvd
-
51:49
straight from the experts: modernizing hyperlipidemia management with pcsk9-targeting agents
-
1:32:53
management of hyperlipidemia in statin-treated or statin-intolerant high-risk ascvd patients
-
1:17:35
ldl-c as a path to reducing cardiovascular events
-
26:59
optimizing ldl-c lowering with pcsk9 inhibition
-
5:41
what is pcsk9 and how pcsk9 inhibitors work? (mechanism of action)
-
23:18
professor kausik ray - pcsk9 inhibition – have we reached the limits of lipid lowering and outcome?
-
20:49
dr aruna pradhan - have we reached the limits of lipid lowering? what next? - full version
-
1:01
patient access to pcsk9 inhibitors
-
57:03
addressing unmet needs among high-risk patients with ascvd with novel lipid-lowering therapies
-
47:59
tools to get to ldl-c target with better adherence: the experts share experiences with new therapies
-
1:03:46
pcsk9 inhibitors within the targeted treatment approach to hypercholesterolemia 4/26/16
-
0:52
the apob cholesterol test: why it matters | dr. robert lustig
-
17:23
lipidology
-
1:04:56
intertwined roles of pcsk9 in lipoprotein metabolism and inflammation - weekly research conference
-
52:07
update on the management of hypercholesterolemia
-
6:00
scientific insights into ldl-c, pcsk9, and cv risks